Van Impe, K., Bethuyne, J., Cool, S., Impens, F., Ruano-Gallego, D., De Wever, O., . . . Gettemans, J. (2013),
A nanobody targeting the F-actin capping protein CapG restrains breast cancer metastasis., Breast Cancer Research : BCR, 15(6), R116. doi:10.1186/bcr3585 [doi]
Jackson TR, Vuorinen A, Josa-Culleré L, Madden KS, Conole D, Cogswell TJ, Wilkinson IVL, Kettyle LM, Zhang D, O'Mahony A, Gracias D, McCall L, Westwood R, Terstappen GC, Davies SG, Tate EW, Wynne GM, Vyas P, Russell AJ, Milne TA.,
A tubulin binding molecule drives differentiation of acute myeloid leukemia cells, iScience. 2022 Jul 19;25(8):104787. doi: 10.1016/j.isci.2022.104787. eCollection 2022 Aug 19.
Zarrinkar, P. P., Gunawardane, R. N., Cramer, M. D., Gardner, M. F., Brigham, D., Belli, B., . . . Bhagwat, S. S. (2009),
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)., Blood, 114(14), 2984-2992. doi:10.1182/blood-2009-05-222034 [doi]
Bruckheimer, E. M., Fazenbaker, C. A., Gallagher, S., Mulgrew, K., Fuhrmann, S., Coffman, K. T., . . . Coats, S. (2009).,
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors., Neoplasia (New York, N.Y.), 11(6), 509-17, 2 p following 517.
Yen, W. C., Fischer, M. M., Hynes, M., Wu, J., Kim, E., Beviglia, L., . . . Hoey, T. (2012),
Anti-DLL4 has broad spectrum activity in pancreatic cancer dependent on targeting DLL4-notch signaling in both tumor and vasculature cells., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 18(19), 5374-5386. doi:10.1158/1078-0432.CCR-12-0736 [doi]
Damelin, M., Bankovich, A., Park, A., Aguilar, J., Anderson, W., Santaguida, M., . . . Dylla, S. J. (2015).,
Anti-EFNA4 calicheamicin conjugates effectively target triple-negative breast and ovarian tumor-initiating cells to result in sustained tumor regressions, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 21(18), 4165-4173. doi:10.1158/1078-0432.CCR-15-0695 [doi]
Hassler, M. R., Klisaroska, A., Kollmann, K., Steiner, I., Bilban, M., Schiefer, A. I., . . . Egger, G. (2012).,
Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma., Biochimie, 94(11), 2297-2307. doi:10.1016/j.biochi.2012.05.029 [doi]
Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, David Lawson J, Gunn RJ, Smith CR, Thomas NC, Martinson M, Bergstrom A, Sullivan F, Bouhana K, Winski S, He L, Fernandez-Banet J, Pavlicek A, Haling JR, Rahbaek L, Marx MA, Olson P, Christensen JG.,
Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor, Nat Med. 2022 Oct;28(10):2171-2182. doi: 10.1038/s41591-022-02007-7. Epub 2022 Oct 10.
Dold, C., Rodriguez Urbiola, C., Wollmann, G., Egerer, L., Muik, A., Bellmann, L., . . . von Laer, D. (2016).,
Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy., Molecular Therapy Oncolytics, 3, 16021. doi:10.1038/mto.2016.21 [doi]
Cosco, D., Paolino, D., De Angelis, F., Cilurzo, F., Celia, C., Di Marzio, L., . . . Fresta, M. (2015),
Aqueous-core PEG-coated PLA nanocapsules for an efficient entrapment of water soluble anticancer drugs and a smart therapeutic response, European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik e.V, 89, 30-39. doi:10.1016/j.ejpb.2014.11.012 [doi]
Was, H., Barszcz, K., Czarnecka, J., Kowalczyk, A., Bernas, T., Uzarowska, E., . . . Sikora, E. (2017).,
Bafilomycin A1 triggers proliferative potential of senescent cancer cells in vitro and in NOD/SCID mice., Oncotarget, 8(6), 9303-9322. doi:10.18632/oncotarget.14066 [doi]
Londono-Joshi, A. I., Oliver, P. G., Li, Y., Lee, C. H., Forero-Torres, A., LoBuglio, A. F., & Buchsbaum, D. J. (2012).,
Basal-like breast cancer stem cells are sensitive to anti-DR5 mediated cytotoxicity, Breast Cancer Research and Treatment, 133(2), 437-445. doi:10.1007/s10549-011-1763-0 [doi]
Khawaja H, Briggs R, Latimer CH, Rassel M, Griffin D, Hanson L, Bardelli A, Di Nicolantonio F, McDade SS, Scott CJ, Lambe S, Maurya M, Lindner AU, Prehn JHM, Sousa J, Winnington C, LaBonte MJ, Ross S, Van Schaeybroeck S.,
Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer., Mol Cancer Ther. 2023 Jan 3;22(1):135-149. doi: 10.1158/1535-7163.MCT-22-0301.
Wang, L., Park, P., Zhang, H., La Marca, F., Claeson, A., Than, K., . . . Lin, C. Y. (2012).,
BMP-2 inhibits tumor growth of human renal cell carcinoma and induces bone formation, International Journal of Cancer.Journal International Du Cancer, 131(8), 1941-1950. doi:10.1002/ijc.27444 [doi]
Wang, L., Park, P., La Marca, F., Than, K., Rahman, S., & Lin, C. Y. (2013).,
Bone formation induced by BMP-2 in human osteosarcoma cells., International Journal of Oncology, 43(4), 1095-1102. doi:10.3892/ijo.2013.2030 [doi]
Gaudio, E., Tarantelli, C., Ponzoni, M., Odore, E., Rezai, K., Bernasconi, E., . . . Bertoni, F. (2016).,
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma, Oncotarget, 7(36), 58142-58147. doi:10.18632/oncotarget.10983 [doi]
Sharma, Sambad; Wu, Shih-Ying; Jimenez, Hugo; Xing, Fei; Zhu, Dongqin; Liu, Yin; Wu, Kerui; Tyagi, Abhishek; Zhao, Dan; Lo, Hui-Wen; Metheny-Barlow, Linda; Sun, Peiqing; Bourland, John D; Chan, Michael D; Thomas, Alexandra; Barbault, Alexandre; DAgostino, Ralph B; Whitlow, Christopher T; Kirchner, Volker; Blackman, Carl; Pasche, Boris; Watabe, Kounosuke;,
Ca2+ and CACNA1H mediate targeted suppression of breast cancer brain metastasis by AM RF EMF., EBioMedicine Vol.44, 2019
Sullivan KMC, Vilalta M, Ertl LS, Wang Y, Dunlap C, Ebsworth K, Zhao BN, Li S, Zeng Y, Miao Z, Fan P, Mali V, Lange C, McMurtrie D, Yang J, Lui R, Scamp R, Chhina V, Kumamoto A, Yau S, Dang T, Easterday A, et al.,
CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity., PLoS One. 2023 Jun 7;18(6):e0286724. doi: 10.1371/journal.pone.0286724. eCollection 2023.
Castelli R, Taranto S, Furiassi L, Bozza N, Marseglia G, Ferlenghi F, Rivara S, Retini M, Bedini A, Spadoni G, Matarazzo S, Ronca R, Presta M, Mor M, Giacomini A.,
Chemical modification of NSC12 leads to a specific FGF-trap with antitumor activity in multiple myeloma, Eur J Med Chem. 2021 Oct 5;221:113529. doi: 10.1016/j.ejmech.2021.113529. Epub 2021 May 5.
Zaoui, K., Bossow, S., Grossardt, C., Leber, M. F., Springfeld, C., Plinkert, P. K., . . . Ungerechts, G. (2012).,
Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus., Cancer Gene Therapy, 19(3), 181-191. doi:10.1038/cgt.2011.75 [doi]
Feng, Yashu; Zhang, Ling; Wu, Jieying; Khadka, Bijay; Fang, Zhigang; Gu, Jiaming; Tang, Baoqiang; Xiao, Ruozhi; Pan, Guangjin; Liu, Jiajun;,
CircRNA circ_0000190 inhibits the progression of multiple myeloma through modulating miR-767-5p/MAPK4 pathway., Journal of experimental & clinical cancer research : CR Vol.38, 2019
Sun, L., Zhang, L., Qian, J., Yang, J., Yi, Q., Dong, W., & Wang, M. (2012).,
Combination of atiprimod and the proteasome inhibitor bortezomib induces apoptosis of mantle cell lymphoma in vitro and in vivo., Leukemia Research, 36(3), 363-368. doi:10.1016/j.leukres.2011.09.014 [doi]
Gaudio, E., Tarantelli, C., Kwee, I., Barassi, C., Bernasconi, E., Rinaldi, A., . . . Bertoni, F. (2016).,
Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas., Annals of Oncology : Official Journal of the European Society for Medical Oncology, 27(6), 1123-1128. doi:10.1093/annonc/mdw131 [doi]
Benguigui, Madeleine; Weitz, Iris S; Timaner, Michael; Kan, Tal; Shechter, Dvir; Perlman, Or; Sivan, Sarit; Raviv, Ziv; Azhari, Haim; Shaked, Yuval;,
Copper oxide nanoparticles inhibit pancreatic tumor growth primarily by targeting tumor initiating cells., Scientific reports Vol.9, 2019
Cosco, D., Cilurzo, F., Maiuolo, J., Federico, C., Di Martino, M. T., Cristiano, M. C., . . . Paolino, D. (2015).,
Delivery of miR-34a by chitosan/PLGA nanoplexes for the anticancer treatment of multiple myeloma., Scientific Reports, 5, 17579. doi:10.1038/srep17579 [doi]
Aasen, Synnøve Nymark; Parajuli, Himalaya; Hoang, Tuyen; Feng, Zichao; Stokke, Krister; Wang, Jiwei; Roy, Kislay; Bjerkvig, Rolf; Knappskog, Stian; Thorsen, Frits;,
Effective Treatment of Metastatic Melanoma by Combining MAPK and PI3K Signaling Pathway Inhibitors., International journal of molecular sciences Vol.20, 2019
Shir, A., Ogris, M., Roedl, W., Wagner, E., & Levitzki, A. (2011),
EGFR-homing dsRNA activates cancer-targeted immune response and eliminates disseminated EGFR-overexpressing tumors in mice, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 17(5), 1033-1043. doi:10.1158/1078-0432.CCR-10-1140 [doi]
Krishnamoorthy, Gnana P; Davidson, Natalie R; Leach, Steven D; Zhao, Zhen; Lowe, Scott W; Lee, Gina; Landa, I?igo; Nagarajah, James; Saqcena, Mahesh; Singh, Kamini; Wendel, Hans-Guido; Dogan, Snjezana; Tamarapu, Prasanna P; Blenis, John; Ghossein, Ronald A; Knauf, Jeffrey A; Rätsch, Gunnar; Fagin, James A,
EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC., Cancer discovery Vol.9, 2019
Suominen MI, Knuuttila M, Schatz CA, Schlicker A, Vääräniemi J, Sjöholm B, Alhoniemi E, Haendler B, Mumberg D, Käkönen SM, Scholz A.,
Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model., Int J Mol Sci. 2023 Jan 22;24(3). pii: 2189. doi: 10.3390/ijms24032189.
La Rocca, Francesco; Airoldi, Irma; Di Carlo, Emma; Marotta, Pina; Falco, Geppino; Simeon, Vittorio; Laurenzana, Ilaria; Trino, Stefania; De Luca, Luciana; Todoerti, Katia; Villani, Oreste; Lackmann, Martin; DAuria, Fiorella; Frassoni, Francesco; Neri, Antonino; Del Vecchio, Luigi; Musto, Pellegrino; Cilloni, Daniela; Caivano, Antonella;,
EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells., Cellular oncology (Dordrecht) Vol.40, 2017
Ronca R, Ghedini GC, Maccarinelli F, Sacco A, Locatelli SL, Foglio E, Taranto S, Grillo E, Matarazzo S, Castelli R, Paganini G, Desantis V, Cattane N, Cattaneo A, Mor M, Carlo-Stella C, Belotti A, Roccaro AM, Presta M, Giacomini A.,
FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation-Induced Mitochondrial Oxidative Stress, Cancer Res. 2020 Jun 1;80(11):2340-2354. doi: 10.1158/0008-5472.CAN-19-2714. Epub 2020 Feb 24.
Paolino, D., Licciardi, M., Celia, C., Giammona, G., Fresta, M., & Cavallaro, G. (2012).,
Folate-targeted supramolecular vesicular aggregates as a new frontier for effective anticancer treatment in in vivo model., European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik e.V, 82(1), 94-102. doi:10.1016/j.ejpb.2012.06.001 [doi]
Paolino, D., Cosco, D., Celano, M., Moretti, S., Puxeddu, E., Russo, D., & Fresta, M. (2013).,
Gemcitabine-loaded biocompatible nanocapsules for the effective treatment of human cancer, Nanomedicine (London, England), 8(2), 193-201. doi:10.2217/nnm.12.101 [doi]
Solimando AG, Da Vià MC, Leone P, Borrelli P, Croci GA, Tabares P, Brandl A, Di Lernia G, Bianchi FP, Tafuri S, Steinbrunn T, Balduini A, Melaccio A, De Summa S, Argentiero A, Rauert-Wunderlich H, Frassanito MA, Ditonno P, Henke E, Klapper W, Ria R, Terragna C, Rasche L, Rosenwald A, Kortüm KM, Cavo M, Ribatti D, Racanelli V, Einsele H, Vacca A, Beilhack A.,
Halting the vicious cycle within the multiple myeloma ecosystem: blocking JAM-A on bone marrow endothelial cells restores the angiogenic homeostasis and suppresses tumor progression, Haematologica. 2020 Apr 30:haematol.2019.239913. doi: 10.3324/haematol.2019.239913. Online ahead of print.
Litzenburger, B. C., Creighton, C. J., Tsimelzon, A., Chan, B. T., Hilsenbeck, S. G., Wang, T., . . . Lee, A. V. (2011),
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 17(8), 2314-2327. doi:10.1158/1078-0432.CCR-10-1903 [doi]
Shin, D. Y., Kim, A., Kang, H. J., Park, S., Kim, D. W., & Lee, S. S. (2015).,
Histone deacetylase inhibitor romidepsin induces efficient tumor cell lysis via selective down-regulation of LMP1 and c-myc expression in EBV-positive diffuse large B-cell lymphoma, Cancer Letters, 364(2), 89-97. doi:10.1016/j.canlet.2015.03.016 [doi]
Lu, Y., Liu, Y., Oeck, S., & Glazer, P. M. (2018).,
Hypoxia promotes resistance to EGFR inhibition in NSCLC cells via the histone demethylases, LSD1 and PLU-1., Molecular Cancer Research : MCR, 16(10), 1458-1469. doi:10.1158/1541-7786.MCR-17-0637 [doi]
Stewart, R., Morrow, M., Hammond, S. A., Mulgrew, K., Marcus, D., Poon, E., . . . McCourt, M. (2015).,
Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody., Cancer Immunology Research, 3(9), 1052-1062. doi:10.1158/2326-6066.CIR-14-0191 [doi]
Buoncervello, M., Romagnoli, G., Buccarelli, M., Fragale, A., Toschi, E., Parlato, S., . . . Gabriele, L. (2016),
IFN-alpha potentiates the direct and immune-mediated antitumor effects of epigenetic drugs on both metastatic and stem cells of colorectal cancer., Oncotarget, 7(18), 26361-26373. doi:10.18632/oncotarget.8379 [doi]
Airoldi, I., Di Carlo, E., Cocco, C., Caci, E., Cilli, M., Sorrentino, C., . . . Pistoia, V. (2009).,
IL-12 can target human lung adenocarcinoma cells and normal bronchial epithelial cells surrounding tumor lesions., PloS One, 4(7), e6119. doi:10.1371/journal.pone.0006119 [doi]
Aasen, Synnøve Nymark; Espedal, Heidi; Holte, Christopher Florian; Keunen, Olivier; Karlsen, Tine Veronika; Tenstad, Olav; Maherally, Zaynah; Miletic, Hrvoje; Hoang, Tuyen; Eikeland, Anne Vaag; Baghirov, Habib; Olberg, Dag Erlend; Pilkington, Geoffrey John; Sarkar, Gobinda; Jenkins, Robert B; Sundstrøm, Terje; Bjerkvig, Rolf; Thorsen, Frits;,
Improved Drug Delivery to Brain Metastases by Peptide-Mediated Permeabilization of the Blood-Brain Barrier., Molecular cancer therapeutics Vol.18, 2019
Di Martino, M. T., Gulla, A., Gallo Cantafio, M. E., Altomare, E., Amodio, N., Leone, E., . . . Tassone, P. (2014,
In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells., PloS One, 9(2), e89659. doi:10.1371/journal.pone.0089659 [doi]
Hofmann, M., McCormack, E., Mujic, M., Rossberg, M., Bernd, A., Bereiter-Hahn, J., . . . Kippenberger, S. (2009).,
Increased plasma colloid osmotic pressure facilitates the uptake of therapeutic macromolecules in a xenograft tumor model, Neoplasia (New York, N.Y.), 11(8), 812-822.
Kuang Y, Ye N, Kyani A, Ljungman M, Paulsen M, Chen H, Zhou M, Wild C, Chen H, Zhou J, Neamati N.,
Induction of Genes Implicated in Stress Response and Autophagy by a Novel Quinolin-8-yl-nicotinamide QN523 in Pancreatic Cancer, J Med Chem. 2022 Apr 28;65(8):6133-6156. doi: 10.1021/acs.jmedchem.1c02207. Epub 2022 Apr 19.
Otto, Marius; Blatt, Sebastian; Pabst, Andreas; Mandic, Robert; Schwarz, Johanna; Neff, Andreas; Ziebart, Thomas;,
Influence of buffy coat-derived putative endothelial progenitor cells on tumor growth and neovascularization in oral squamous cell carcinoma xenografts., Clinical oral investigations Vol.23, 2019
Boer, J. C., Domanska, U. M., Timmer-Bosscha, H., Boer, I. G., de Haas, C. J., Joseph, J. V., . . . Walenkamp, A. M. (2013),
Inhibition of formyl peptide receptor in high-grade astrocytoma by CHemotaxis inhibitory protein of S. aureus., British Journal of Cancer, 108(3), 587-596. doi:10.1038/bjc.2012.603 [doi]
Lamanuzzi, A., Saltarella, I., Desantis, V., Frassanito, M. A., Leone, P., Racanelli, V., . . . Ria, R. (2018).,
Inhibition of mTOR complex 2 restrains tumor angiogenesis in multiple myeloma., Oncotarget, 9(29), 20563-20577. doi:10.18632/oncotarget.25003 [doi]
Rodriguez-Barrueco, R., Yu, J., Saucedo-Cuevas, L. P., Olivan, M., Llobet-Navas, D., Putcha, P., . . . Silva, J. M. (2015).,
Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers, Genes & Development, 29(15), 1631-1648. doi:10.1101/gad.262642.115 [doi]
Burns, T. F., Dobromilskaya, I., Murphy, S. C., Gajula, R. P., Thiyagarajan, S., Chatley, S. N., . . . Rudin, C. M. (2013).,
Inhibition of TWIST1 leads to activation of oncogene-induced senescence in oncogene-driven non-small cell lung cancer, Molecular Cancer Research : MCR, 11(4), 329-338. doi:10.1158/1541-7786.MCR-12-0456 [doi]
Wang T, Gnanaprakasam JNR, Chen X, Kang S, Xu X, Sun H, Liu L, Rodgers H, Miller E, Cassel TA, Sun Q, Vicente-MuĂąoz S, Warmoes MO, Lin P, Piedra-Quintero ZL, Guerau-de-Arellano M, Cassady KA, Zheng SG, Yang J, Lane AN, Song X, Fan TW, Wang R.,
Inosine is an alternative carbon source for CD8(+)-T-cell function under glucose restriction, Nat Metab. 2020 Jul;2(7):635-647. doi: 10.1038/s42255-020-0219-4. Epub 2020 Jun 15.
Haas, T. L., Sciuto, M. R., Brunetto, L., Valvo, C., Signore, M., Fiori, M. E., . . . De Maria, R. (2017).,
Integrin alpha7 is a functional marker and potential therapeutic target in glioblastoma, Cell Stem Cell, 21(1), 35-50.e9. doi:S1934-5909(17)30137-6 [pii]
Cocco, C., Giuliani, N., Di Carlo, E., Ognio, E., Storti, P., Abeltino, M., . . . Airoldi, I. (2010),
Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 16(16), 4188-4197. doi:10.1158/1078-0432.CCR-10-0173 [doi]
Airoldi, I., Tupone, M. G., Esposito, S., Russo, M. V., Barbarito, G., Cipollone, G., & Di Carlo, E. (2015).,
Interleukin-27 re-educates intratumoral myeloid cells and down-regulates stemness genes in non-small cell lung cancer., Oncotarget, 6(6), 3694-3708. doi:2797 [pii]
Fan F, Malvestiti S, Vallet S, Lind J, Garcia-Manteiga JM, Morelli E, Jiang Q, Seckinger A, Hose D, Goldschmidt H, Stadlbauer A, Sun C, Mei H, Pecherstorfer M, Bakiri L, Wagner EF, Tonon G, Sattler M, Hu Y, Tassone P, Jaeger D, Podar K.,
JunB is a key regulator of multiple myeloma bone marrow angiogenesis, Leukemia. 2021 Dec;35(12):3509-3525. doi: 10.1038/s41375-021-01271-9. Epub 2021 May 18.
Lapenta, Caterina; Donati, Simona; Spadaro, Francesca; Lattanzi, Laura; Urbani, Francesca; Macchia, Iole; Sestili, Paola; Spada, Massimo; Cox, Maria Christina; Belardelli, Filippo; Santini, Stefano M,
Lenalidomide improves the therapeutic effect of an interferon-Îą-dendritic cell-based lymphoma vaccine., Cancer immunology, immunotherapy : CII Vol.68, 2019
Balvers, R. K., Belcaid, Z., van den Hengel, S. K., Kloezeman, J., de Vrij, J., Wakimoto, H., . . . Lamfers, M. L. (2014).,
Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma., Viruses, 6(8), 3080-3096. doi:10.3390/v6083080 [doi]
Pascual-Pasto G, Resa-Pares C, Castillo-Ecija H, Aschero R, Baulenas-Farres M, Vila-Ubach M, Burgueño V, Balaguer-Lluna L, Cuadrado-Vilanova M, Olaciregui NG, Martinez-Velasco N, Perez-Jaume S, de Alava E, Tirado OM, Lavarino C, Mora J, Carcaboso AM.,
Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma, Biochem Pharmacol. 2023 Jan 2;208:115408. doi: 10.1016/j.bcp.2022.115408. Online ahead of print.
Zhou J, Sturtevant D, Love C, Kulkarni A, Biyani N, Kathad U, Thacker E, Dave S, Bhatia K.,
LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair., Oncotarget. 2023 Jun 12;14:597-611. doi: 10.18632/oncotarget.28454.
Sato H, Schoenfeld AJ, Siau E, Lu YC, Tai H, Suzawa K, Kubota D, Lui AJW, Qeriqi B, Mattar M, Offin M, Sakaguchi M, Toyooka S, Drilon A, Rosen NX, Kris MG, Solit D, De Stanchina E, Davare MA, Riely GJ, Ladanyi M, Somwar R.,
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions, Clin Cancer Res. 2020 Jun 15;26(12):2932-2945. doi: 10.1158/1078-0432.CCR-19-3321. Epub 2020 Mar 2.
Novoplansky, Ofra; Fury, Matthew; Prasad, Manu; Yegodayev, Ksenia; Zorea, Jonathan; Cohen, Limor; Pelossof, Raphael; Cohen, Liz; Katabi, Nora; Cecchi, Fabiola; Joshua, Ben-Zion; Popovtzer, Aron; Baselga, Jose; Scaltriti, Maurizio; Elkabets, Moshe;,
MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer, International journal of cancer Vol.145, 2019
Lynam-Lennon, N., Heavey, S., Sommerville, G., Bibby, B. A., Ffrench, B., Quinn, J., . . . Maher, S. G. (2017).,
MicroRNA-17 is downregulated in esophageal adenocarcinoma cancer stem-like cells and promotes a radioresistant phenotype, Oncotarget, 8(7), 11400-11413. doi:10.18632/oncotarget.13940 [doi]
Baertsch, M. A., Leber, M. F., Bossow, S., Singh, M., Engeland, C. E., Albert, J., . . . Ungerechts, G. (2014),
MicroRNA-mediated multi-tissue detargeting of oncolytic measles virus., Cancer Gene Therapy, 21(9), 373-380. doi:10.1038/cgt.2014.40 [doi]
Liu, R., Shi, P., Nie, Z., Liang, H., Zhou, Z., Chen, W., . . . Chen, C. (2016).,
Mifepristone suppresses basal triple-negative breast cancer stem cells by down-regulating KLF5 expression., Theranostics, 6(4), 533-544. doi:10.7150/thno.14315 [doi]
Parvin, Salma; Ramirez-Labrada, Ariel; Aumann, Shlomzion; Lu, XiaoQing; Weich, Natalia; Santiago, Gabriel; Cortizas, Elena M; Sharabi, Eden; Zhang, Yu; Sanchez-Garcia, Isidro; Gentles, Andrew J; Roberts, Evan; Bilbao-Cortes, Daniel; Vega, Francisco; Chapman, Jennifer R; Verdun, Ramiro E; Lossos, Izidore S;,
MO2 Confers Synthetic Lethality to PARP Inhibition in DLBCL, Cancer cell Vol.36, 2019
Wennier, S. T., Liu, J., Li, S., Rahman, M. M., Mona, M., & McFadden, G. (2012).,
Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer., Molecular Therapy : The Journal of the American Society of Gene Therapy, 20(4), 759-768. doi:10.1038/mt.2011.293 [doi]
Chao, M. W., Chu, P. C., Chuang, H. C., Shen, F. H., Chou, C. C., Hsu, E. C., . . . Chen, C. S. (2016).,
Non-epigenetic function of HDAC8 in regulating breast cancer stem cells by maintaining Notch1 protein stability., Oncotarget, 7(2), 1796-1807. doi:10.18632/oncotarget.6427 [doi]
Giovannini, C., Baglioni, M., Baron Toaldo, M., Ventrucci, C., D'Adamo, S., Cipone, M., . . . Bolondi, L. (2013).,
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma., Oncotarget, 4(10), 1618-1631. doi:1221 [pii]
Moschetta, M., Basile, A., Ferrucci, A., Frassanito, M. A., Rao, L., Ria, R., . . . Vacca, A. (2013).,
Novel targeting of phospho-cMET overcomes drug resistance and induces antitumor activity in multiple myeloma., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 19(16), 4371-4382. doi:10.1158/1078-0432.CCR-13-0039 [doi]
Garg, G., Gibbs, J., Belt, B., Powell, M. A., Mutch, D. G., Goedegebuure, P., . . . Spitzer, D. (2014).,
Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein meso-TR3., BMC Cancer, 14, 35-2407-14-35. doi:10.1186/1471-2407-14-35 [doi]
Santoro, Angela; Vlachou, Thalia; Luzi, Lucilla; Melloni, Giorgio; Mazzarella, Luca; DElia, Errico; Aobuli, Xieraili; Pasi, Cristina Elisabetta; Reavie, Linsey; Bonetti, Paola; Punzi, Simona; Casoli, Lucia; Sab??, Arianna; Moroni, Maria Cristina; Dellino, Gaetano Ivan; Amati, Bruno; Nicassio, Francesco; Lanfrancone, Luisa; Pelicci, Pier Giuseppe;,
p53 Loss in Breast Cancer Leads to Myc Activation, Increased Cell Plasticity, and Expression of a Mitotic Signature with Prognostic Value, Cell reports Vol.26, 2019
Ronca R, Taranto S, Corsini M, Tobia C, Ravelli C, Rezzola S, Belleri M, De Cillis F, Cattaneo A, Presta M, Giacomini A.,
Pentraxin 3 Inhibits the Angiogenic Potential of Multiple Myeloma Cells, Cancers (Basel). 2021 May 8;13(9):2255. doi: 10.3390/cancers13092255.
Pleniceanu, O., Shukrun, R., Omer, D., Vax, E., Kanter, I., Dziedzic, K., . . . Dekel, B. (2017).,
Peroxisome proliferator-activated receptor gamma (PPARgamma) is central to the initiation and propagation of human angiomyolipoma, suggesting its potential as a therapeutic target, EMBO Molecular Medicine, 9(4), 508-530. doi:10.15252/emmm.201506111 [doi]
Spriano F, Sartori G, Tarantelli C, Barreca M, Golino G, Rinaldi A, Napoli S, Mascia M, Scalise L, Arribas AJ, Cascione L, Zucca E, Stathis A, Gaudio E, Bertoni F.,
Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma, EJHaem. 2022 Jul 27;3(3):764-774. doi: 10.1002/jha2.535. eCollection 2022 Aug.
Zhu, C., Cheng, K. W., Ouyang, N., Huang, L., Sun, Y., Constantinides, P., & Rigas, B. (2012).,
Phosphosulindac (OXT-328) selectively targets breast cancer stem cells in vitro and in human breast cancer xenografts., Stem Cells (Dayton, Ohio), 30(10), 2065-2075. doi:10.1002/stem.1139 [doi]
Kolev, V. N., Wright, Q. G., Vidal, C. M., Ring, J. E., Shapiro, I. M., Ricono, J., . . . Xu, Q. (2015).,
PI3K/mTOR dual inhibitor VS-5584 preferentially targets cancer stem cells., null
Di Meo, C., Cilurzo, F., Licciardi, M., Scialabba, C., Sabia, R., Paolino, D., . . . Matricardi, P. (2015).,
Polyaspartamide-doxorubicin conjugate as potential prodrug for anticancer therapy., Pharmaceutical Research, 32(5), 1557-1569. doi:10.1007/s11095-014-1557-2 [doi]
Deb G, Wingelhofer B, Amaral FMR, Maiques-Diaz A, Chadwick JA, Spencer GJ, Williams EL, Leong HS, Maes T, Somervaille TCP.,
Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia, Leukemia. 2020 May;34(5):1266-1277. doi: 10.1038/s41375-019-0659-6. Epub 2019 Nov 28.
Torres-Guzman, R., Calsina, B., Hermoso, A., Baquero, C., Alvarez, B., Amat, J., . . . Lallena, M. J. (2017).,
Preclinical characterization of abemaciclib in hormone receptor positive breast cancer., Oncotarget, 8(41), 69493-69507. doi:10.18632/oncotarget.17778 [doi]
Friedrich, M., Henn, A., Raum, T., Bajtus, M., Matthes, K., Hendrich, L., . . . Rattel, B. (2014).,
Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia., Molecular Cancer Therapeutics, 13(6), 1549-1557. doi:10.1158/1535-7163.MCT-13-0956 [doi]
Hammer S, Hagemann UB, Zitzmann-Kolbe S, Larsen A, Ellingsen C, Geraudie S, Grant D, Indrevoll B, Smeets R, von Ahsen O, Kristian A, Lejeune P, Hennekes H, Karlsson J, Bjerke RM, Ryan OB, Cuthbertson AS, Mumberg D.,
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer, Clin Cancer Res. 2020 Apr 15;26(8):1985-1996. doi: 10.1158/1078-0432.CCR-19-2268. Epub 2019 Dec 12.
Hammer, Stefanie; Hagemann, Urs B; Zitzmann-Kolbe, Sabine; Larsen, Aasmund; Ellingsen, Christine; Geraudie, Solene; Grant, Derek; Indrevoll, Baard; Smeets, Roger; von Ahsen, Oliver; Kristian, Alexander; Lejeune, Pascale; Hennekes, Hartwig; Karlsson, Jenny; Bjerke, Roger M; Ryan, Olav B; Cuthbertson, Alan S; Mumberg, Dominik;,
Preclinical efficacy of a PSMA-targeted thorium-227 conjugate (PSMA-TTC), a targeted alpha therapy for prostate cancer., Clinical cancer research : an official journal of the American Association for Cancer Research Vol.9, 2019
Sommer, A., Kopitz, C., Schatz, C. A., Nising, C. F., Mahlert, C., Lerchen, H. G., . . . Kreft, B. (2016).,
Preclinical efficacy of the auristatin-based antibody-drug conjugate BAY 1187982 for the treatment of FGFR2-positive solid tumors, Cancer Research, 76(21), 6331-6339. doi:0008-5472.CAN-16-0180 [pii]
Smit, J. K., Faber, H., Niemantsverdriet, M., Baanstra, M., Bussink, J., Hollema, H., . . . Coppes, R. P. (2013).,
Prediction of response to radiotherapy in the treatment of esophageal cancer using stem cell markers., Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology, 107(3), 434-441. doi:10.1016/j.radonc.2013.03.027 [doi]
Kim, S., Jin, H., Seo, H. R., Lee, H. J., & Lee, Y. S. (2018).,
Regulating BRCA1 protein stability by cathepsin S-mediated ubiquitin degradation., Cell Death and Differentiation, doi:10.1038/s41418-018-0153-0 [doi]
Amodio, Nicola; Gallo Cantafio, Maria Eugenia; Botta, Cirino; Agosti, Valter; Federico, Cinzia; Caracciolo, Daniele; Ronchetti, Domenica; Rossi, Marco; Driessen, Christoph; Neri, Antonino; Tagliaferri, Pierosandro; Tassone, Pierfrancesco;,
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma, Cancers Vol.11, 2019
Badarni, Mai; Prasad, Manu; Balaban, Noa; Zorea, Jonathan; Yegodayev, Ksenia M; Joshua, Ben-Zion; Dinur, Anat Bahat; GrĂŠnman, Reidar; Rotblat, Barak; Cohen, Limor; Elkabets, Moshe,
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy, JCI insight Vol.5, 2019
Smith BD, Kaufman MD, Lu WP, Gupta A, Leary CB, Wise SC, Rutkoski TJ, Ahn YM, Al-Ani G, Bulfer SL, Caldwell TM, Chun L, Ensinger CL, Hood MM, McKinley A, Patt WC, Ruiz-Soto R, Su Y, Telikepalli H, Town A, Turner BA, Vogeti L, Vogeti S, Yates K, Janku F, Abdul Razak AR, Rosen O, Heinrich MC, Flynn DL.,
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants., Cancer Cell. 2019 May 13;35(5):738-751.e9
D'Alesio, C., Punzi, S., Cicalese, A., Fornasari, L., Furia, L., Riva, L., . . . Lanfrancone, L. (2016).,
RNAi screens identify CHD4 as an essential gene in breast cancer growth, Oncotarget, 7(49), 80901-80915. doi:10.18632/oncotarget.12646 [doi]
Sebastiani J, Puxeddu M, Nalli M, Bai R, Altieri L, Rovella P, Gaudio E, Trisciuoglio D, Spriano F, Lavia P, Fionda C, Masci D, Urbani A, Bigogno C, Dondio G, Hamel E, Bertoni F, Silvestri R, La Regina G.,
RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor in vivo, Eur J Med Chem. 2023 Jan 15;246:114997. doi: 10.1016/j.ejmech.2022.114997. Epub 2022 Dec 5.
Sebastiani J, Puxeddu M, Nalli M, Bai R, Altieri L, Rovella P, Gaudio E, Trisciuoglio D, Spriano F, Lavia P, Fionda C, Masci D, Urbani A, Bigogno C, Dondio G, Hamel E, Bertoni F, Silvestri R, La Regina G.,
RS6077 induces mitotic arrest and selectively activates cell death in human cancer cell lines and in a lymphoma tumor in vivo., Eur J Med Chem. 2023 Jan 15;246:114997. doi: 10.1016/j.ejmech.2022.114997. Epub 2022 Dec 5.
Fischer, M. M., Yeung, V. P., Cattaruzza, F., Hussein, R., Yen, W. C., Murriel, C., . . . Hoey, T. (2017).,
RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common wnt pathway mutations., Scientific Reports, 7(1), 15270-017-15704-y. doi:10.1038/s41598-017-15704-y [doi]
Spriano, Filippo; Tarantelli, Chiara; Gaudio, Eugenio; Gerlach, Magdalena M; Priebe, Valdemar; Cascione, Luciano; Bernasconi, Elena; Targa, Altea; Mascia, Michele; Dirnhofer, Stefan; Stathis, Anastasios; Zucca, Emanuele; Bertoni, Francesco;,
Single and combined BTK and PI3Kδ inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas., British journal of haematology Vol.187, 2019
He, M., Tan, B., Vasan, K., Yuan, H., Cheng, F., Ramos da Silva, S., . . . Gao, S. J. (2017).,
SIRT1 and AMPK pathways are essential for the proliferation and survival of primary effusion lymphoma cells, The Journal of Pathology, 242(3), 309-321. doi:10.1002/path.4905 [doi]
Pascual-Pasto G, Castillo-Ecija H, Unceta N, Aschero R, Resa-Pares C, Gómez-Caballero A, Vila-Ubach M, Muñoz-Aznar O, Suñol M, Burgueño V, Gomez-Gonzalez S, Sosnik A, Ibarra M, Schaiquevich P, de Álava E, Tirado OM, Mora J, Carcaboso AM.,
SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas, J Control Release. 2022 Feb;342:81-92. doi: 10.1016/j.jconrel.2021.12.035. Epub 2021 Dec 30.
Li, X., Wu, J. B., Li, Q., Shigemura, K., Chung, L. W., & Huang, W. C. (2016).,
SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-myc in prostate cancer., Oncotarget, 7(11), 12869-12884. doi:10.18632/oncotarget.7331 [doi]
Mensah AA, Spriano F, Sartori G, Priebe V, Cascione L, Gaudio E, Tarantelli C, Civanelli E, Aresu L, Rinaldi A, Damia G, Lovati E, Zucca E, Stathis A, Pietra C, Bertoni F.,
Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors, Blood Adv. 2021 May 25;5(10):2467-2480. doi: 10.1182/bloodadvances.2020003566.
Patyna, S., Laird, A. D., Mendel, D. B., O'farrell, A. M., Liang, C., Guan, H., . . . Hu-Lowe, D. (2006).,
SU14813: A novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity, Molecular Cancer Therapeutics, 5(7), 1774-1782. doi:5/7/1774 [pii]
Melis, M. H., Simpson, K. L., Dovedi, S. J., Welman, A., MacFarlane, M., Dive, C., . . . Illidge, T. M. (2013).,
Sustained tumour eradication after induced caspase-3 activation and synchronous tumour apoptosis requires an intact host immune response, Cell Death and Differentiation, 20(5), 765-773. doi:10.1038/cdd.2013.8 [doi]
Galuppo, R., Maynard, E., Shah, M., Daily, M. F., Chen, C., Spear, B. T., & Gedaly, R. (2014).,
Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/beta-catenin pathways, Anticancer Research, 34(4), 1709-1713. doi:34/4/1709 [pii]
Rao, L., De Veirman, K., Giannico, D., Saltarella, I., Desantis, V., Frassanito, M. A., . . . Vacca, A. (2018).,
Targeting angiogenesis in multiple myeloma by the VEGF and HGF blocking DARPin((R)) protein MP0250: A preclinical study, Oncotarget, 9(17), 13366-13381. doi:10.18632/oncotarget.24351 [doi]
Zhang X, Huang Z, Wang J, Ma Z, Yang J, Corey E, Evans CP, Yu AM, Chen HW.,
Targeting Feedforward Loops Formed by Nuclear Receptor ROR? and Kinase PBK in mCRPC with Hyperactive AR Signaling, Cancers (Basel). 2021 Apr 1;13(7):1672. doi: 10.3390/cancers13071672.
Leone, E., Morelli, E., Di Martino, M. T., Amodio, N., Foresta, U., Gulla, A., . . . Tassone, P. (2013).,
Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 19(8), 2096-2106. doi:10.1158/1078-0432.CCR-12-3325 [doi]
Raimondi, L., Amodio, N., Di Martino, M. T., Altomare, E., Leotta, M., Caracciolo, D., . . . Tassone, P. (2014),
Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: In vitro and in vivo anti-tumor activity, Oncotarget, 5(10), 3039-3054. doi:1747 [pii]
Stafman, L. L., Mruthyunjayappa, S., Waters, A. M., Garner, E. F., Aye, J. M., Stewart, J. E., . . . Beierle, E. A. (2018).,
Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma., Oncotarget, 9(32), 22665-22679. doi:10.18632/oncotarget.25205 [doi]
Gedaly, R., Galuppo, R., Daily, M. F., Shah, M., Maynard, E., Chen, C., . . . Spear, B. T. (2014).,
Targeting the Wnt/beta-catenin signaling pathway in liver cancer stem cells and hepatocellular carcinoma cell lines with FH535., PloS One, 9(6), e99272. doi:10.1371/journal.pone.0099272 [doi]
Scionti F, Juli G, Rocca R, Polerà N, Nadai M, Grillone K, Caracciolo D, Riillo C, Altomare E, Ascrizzi S, Caparello B, Cerra M, Arbitrio M, Richter SN, Artese A, Alcaro S, Tagliaferri P, Tassone P, Di Martino MT.,
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma., J Exp Clin Cancer Res. 2023 Mar 27;42(1):71. doi: 10.1186/s13046-023-02633-0.
Davidi, S., Fremder, E., Kan, T., Raviv, Z., Timaner, M., Karin, N., . . . Shaked, Y. (2017),
The antiangiogenic role of the pro-inflammatory cytokine interleukin-31., Oncotarget, 8(10), 16430-16444. doi:10.18632/oncotarget.14857 [doi]
Boi, M., Gaudio, E., Bonetti, P., Kwee, I., Bernasconi, E., Tarantelli, C., . . . Bertoni, F. (2015).,
The BET bromodomain inhibitor OTX015 affects pathogenetic pathways in preclinical B-cell tumor models and synergizes with targeted drugs., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 21(7), 1628-1638. doi:10.1158/1078-0432.CCR-14-1561 [doi]
Laurent, S., Queirolo, P., Boero, S., Salvi, S., Piccioli, P., Boccardo, S., . . . Pistillo, M. P. (2013).,
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production., Journal of Translational Medicine, 11, 108-5876-11-108. doi:10.1186/1479-5876-11-108 [doi]
Adam, C., Baeurle, A., Brodsky, J. L., Wipf, P., Schrama, D., Becker, J. C., & Houben, R. (2014),
The HSP70 modulator MAL3-101 inhibits merkel cell carcinoma., PloS One, 9(4), e92041. doi:10.1371/journal.pone.0092041 [doi]
Fareh, M., Turchi, L., Virolle, V., Debruyne, D., Almairac, F., de-la-Forest Divonne, S., . . . Virolle, T. (2012).,
The miR 302-367 cluster drastically affects self-renewal and infiltration properties of glioma-initiating cells through CXCR4 repression and consequent disruption of the SHH-GLI-NANOG network., Cell Death and Differentiation, 19(2), 232-244. doi:10.1038/cdd.2011.89 [doi]
Ordonez, J. L., Amaral, A. T., Carcaboso, A. M., Herrero-Martin, D., del Carmen Garcia-Macias, M., Sevillano, V., . . . de Alava, E. (2015,
The PARP inhibitor olaparib enhances the sensitivity of ewing sarcoma to trabectedin, Oncotarget, 6(22), 18875-18890. doi:10.18632/oncotarget.4303 [doi]
Abbruzzese, C., Catalogna, G., Gallo, E., di Martino, S., Mileo, A. M., Carosi, M., . . . Paggi, M. G. (2017).,
The small molecule SI113 synergizes with mitotic spindle poisons in arresting the growth of human glioblastoma multiforme., Oncotarget, 8(67), 110743-110755. doi:10.18632/oncotarget.22500 [doi]
Komar-Stossel, C., Gross, E., Dery, E., Corchia, N., Meir, K., Fried, I., & Abramovitch, R. (2014),
TL-118 and gemcitabine drug combination display therapeutic efficacy in a MYCN amplified orthotopic neuroblastoma murine model--evaluation by MRI, PloS One, 9(3), e90224. doi:10.1371/journal.pone.0090224 [doi]
Cheng, K. W., Mattheolabakis, G., Wong, C. C., Ouyang, N., Huang, L., Constantinides, P. P., & Rigas, B. (2012).,
Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer., International Journal of Oncology, 41(4), 1199-1203. doi:10.3892/ijo.2012.1577 [doi]
Qin A, Qin Y, Lee J, Musket A, Ying M, Krenciute G, Marincola FM, Yao ZQ, Musich PR, Xie Q.,
Tyrosine kinase signaling-independent MET-targeting with CAR-T cells, J Transl Med. 2023 Oct 1;21(1):682. doi: 10.1186/s12967-023-04521-9.
Signore, M., Buccarelli, M., Pilozzi, E., De Luca, G., Cappellari, M., Fanciulli, M., . . . Ricci-Vitiani, L. (2016).,
UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response, Oncotarget, 7(28), 44113-44128. doi:10.18632/oncotarget.9859 [doi]
Dey, J., Deckwerth, T. L., Kerwin, W. S., Casalini, J. R., Merrell, A. J., Grenley, M. O., . . . Klinghoffer, R. A. (2017).,
Voruciclib, a clinical stage oral CDK9 inhibitor, represses MCL-1 and sensitizes high-risk diffuse large B-cell lymphoma to BCL2 inhibition, Scientific Reports, 7(1), 18007-017-18368-w. doi:10.1038/s41598-017-18368-w [doi]
Punzi, Simona; Balestrieri, Chiara; DAlesio, Carolina; Bossi, Daniela; Dellino, Gaetano Ivan; Gatti, Elena; Pruneri, Giancarlo; Criscitiello, Carmen; Lovati, Giulia; Meliksetyan, Marine; Carugo, Alessandro; Curigliano, Giuseppe; Natoli, Gioacchino; Pelicci, Pier Giuseppe; Lanfrancone, Luisa;,
WDR5 inhibition halts metastasis dissemination by repressing the mesenchymal phenotype of breast cancer cells., Breast cancer research : BCR Vol.21, 2019
Fischer, M. M., Cancilla, B., Yeung, V. P., Cattaruzza, F., Chartier, C., Murriel, C. L., . . . Hoey, T. (2017).,
WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death, Science Advances, 3(6), e1700090. doi:10.1126/sciadv.1700090 [doi]
Sabatino, M. A., Geroni, C., Ganzinelli, M., Ceruti, R., & Broggini, M. (2013).,
Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin, Epigenetics, 8(6), 656-665. doi:10.4161/epi.24916 [doi]